Hormones control essential processes like growth, metabolism, mood, and reproduction, but when their balance is disrupted, it ...
Management maintained guidance for net cash used in operations in 2025 between $340 million and $370 million and reiterated, "existing cash and investments will be sufficient to fund our operations ...
Acromegaly is a rare disease that causes facial and skeletal bone deformities, as well as heart complications, diabetes and cancer It is diagnosed around 10 years after its onset; its World Day is ...
“It didn’t get crazy until he hit puberty when he was 12, 13, and he was already over 6 feet and still growing two and three inches every year,” Gabriel Yates' mom says Susan Young is a reporter. She ...
Paltusotine is the first once-daily oral therapy approved for acromegaly, offering a non-invasive alternative to injections. PATHFNDR-1 and PATHFNDR-2 trials showed significant efficacy in IGF-1 ...
Credit: Crinetics. Palsonify is supplied as a 20mg and 30mg tablet. Palsonify is an oral, selectively-targeted somatostatin receptor type 2 nonpeptide agonist. The Food and Drug Administration (FDA) ...
SAN DIEGO — Crinetics Pharmaceuticals won Food and Drug Administration approval on Thursday for a drug for a rare and debilitating hormonal disorder — the company’s first approved product. But the ...
Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. SAN DIEGO — Crinetics Pharmaceuticals won Food and Drug Administration approval on ...
IGF-1 levels remained stable at week 96 for PATHFNDR-1 patients switched to oral palsonify. Daily symptom flares dropped from over 30% on injectables to 6.2% with palsonify in PATHFNDR-1. Get a Year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results